Delivery Order SPE2DB20D9329-SPE2DB25FZK29
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 11, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). This award, issued on June 3, 2025, with an ultimate completion date of June 4, 2025, represents a single delivery order under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA valued at approximately $500 million through November 2026. The delivery will be fulfilled from the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The awardee, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its location in the same city....
- The Defense Logistics Agency awarded a $4,169.59 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on June 18, 2025, for the supply of Xtandi 80 mg tablets (60-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its primary location. This delivery order was issued without a set-aside designation, and the ultimate completion date is June 20, 2025. The contract leverages DMS...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, which became effective on July 23, 2025, with an ultimate completion date of July 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg tablets (120-count). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge facility. This delivery order was awarded without set-aside designation on September 18, 2025, with an ultimate completion date of September 19, 2025. This award is...
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc. on August 20, 2025, for 60 tablets of Xtandi 80 mg. This delivery order, which is set to be completed by August 21, 2025, represents a firm fixed-price contract with no set-aside designation. The product will be delivered to Park Ridge, Illinois, where the awardee is headquartered. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was selected to fulfill...
- On June 18, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count unit). This firm fixed-price delivery order is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which carries a total value of $499,999,999 and remains valid through November 2026. The ultimate completion date for this delivery order is June 20, 2025,...
- The Defense Logistics Agency awarded a $4,169.59 delivery order to DMS Pharmaceutical Group Inc. on September 5, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, designated 4569340914, is scheduled for completion by September 8, 2025, and will be performed at the vendor's facility in Park Ridge, Illinois. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an open basis despite its status as a...
- SPE2DB20D9329Indefinite Delivery Contract
- SPE2DB20D9329-SPE2DB25FZK29Delivery Order
The Defense Logistics Agency awarded a $8,339.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on May 30, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The award, effective through June 2, 2025, carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its Park Ridge location. The company has been registered in the System for Award Management since 2001 and specializes in distributing branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to federal healthcare systems. This delivery order is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the Defense Logistics Agency through the SPE2DB program, valued at $499,999,999 and valid through November 2026. This master contract enables DLA to procure a comprehensive portfolio of pharmaceutical products supporting medical supply needs across Department of Defense healthcare facilities worldwide. Xtandi, an oncology medication, exemplifies the specialized pharmaceutical products that DMS Pharmaceutical Group routinely provides through this vehicle. The company's consistent contract awards and established role as a key supplier in the federal pharmaceutical supply chain underscore its significance in supporting military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 5/30/25 |